503614-97-9

Basic information

• Product Name: Benzoic acid, 4-(2-oxo-1-piperidinyl)-, methyl ester
• CAS NO: 503614-97-9
• Molecular Formula: C13H15NO3
• Molecular Weight: 233.267
• Mol File: 503614-97-9.mol
• Article Data: 6

Chemical Properties

• Melting Point: 120-121 °C
• Boiling Point: 456.2±28.0 °C(Predicted)
• Density: 1.189±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Benzoic acid, 4-(2-oxo-1-piperidinyl)-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-(2-oxo-1-piperidinyl)-, methyl ester(503614-97-9)
• EPA Substance Registry System: Benzoic acid, 4-(2-oxo-1-piperidinyl)-, methyl ester(503614-97-9)

Safety Data

• Hazardous Substances Data: 503614-97-9(Hazardous Substances Data)

Upstream product

• 889129-50-4 4-(5-chloro-pentanoylamino)-benzoic acid methyl ester 
• 675-20-7 piperidin-2-one 
• 619-44-3 methyl 4-iodobenzoate 
• 1575-61-7 5-Chlorovaleroyl chloride 
• 619-45-4 4-methoxycarbonyl aniline 
• 1126-46-1 Methyl 4-chlorobenzoate 
• 619-42-1 4-methoxycarbonylphenyl bromide 

Downstream Products

• 175153-03-4 4-[(2-oxo-piperidine)-1-yl]benzoic acid 
• 503613-45-4 5-chloro-N-(5-chloropyridin-2-yl)-3-methoxy-2-[4-(2-oxopiperidin-1-yl)benzoylamino]benzamide 
• 503613-37-4 5-chloro-N-(5-chloropyridin-2-yl)-2-({4-[(2-oxopiperidine)-1-yl]benzoyl}amino)benzamide 

Relevant articles and documents

Ring size changes in the development of class I HDAC inhibitors

Five pathways involving different ring structures led to generation of fourteen thienylbenzamides (7–20) which display the structure-activity relationships of class I HDAC inhibitors. All the synthesised compounds inhibit HDAC1 and HDAC2 selectively over other isoforms and many inhibit DLD1 and HCT116 cells more effectively than a parent compound. Compounds 8 and 16 inhibit HCT116 cells by activation of the apoptosis pathway.

Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties

Introduction of the phenyl piperidinone and phenyl pyridinone P4 moieties in the anthranilamide scaffold led to potent, selective, and orally bioavailable inhibitors of factor Xa. Anthranilamide 28 displayed comparable efficacy to apixaban in the rabbit a

PROCESS FOR PRODUCING 3-ACYLAMINOBENZOFURAN-2-CARBOXYLIC ACID DERIVATIVE

The present invention provides a process of preparing a compound of the formula [I]: wherein X is a group of the formula: -N="or" -CH=; R1 is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a cyano group or an amino group optionally substituted by a lower alkyl group; Ring A is a nitrogen-containing heterocyclic group; Ring B is an optionally substituted benzene ring or an optionally substituted pyridine ring; and R3 is a hydrogen atom or a lower alkyl group, or a pharmaceutically acceptable salt thereof , which is useful as an inhibitor of activated blood coagulation factor X.